Clinical Trials Logo

Clinical Trial Summary

The primary objective of the study is to determine the safety and tolerability of 89Zr-DFO-REGN3504. The secondary objectives of the study are: Study Part A only: - To establish adequate mass dose and activity dose of 89Zr˗DFO˗REGN3504 and optimal post-infusion imaging time, as assessed by imaging and blood draw after tracer infusion Study Part B only: - To establish test/re-test reliability of positron emission tomography (PET) measures as assessed on 2 separate tracer infusions at adequate mass dose and optimal imaging time point as determined in Part A - To characterize the pharmacokinetic (PK) profile of 89Zr˗DFO˗REGN3504 based on tracer plasma activity concentration

Clinical Trial Description


Study Design

Related Conditions & MeSH terms

  • Advanced PD-L1 Positive Malignancies
  • Neoplasms

NCT number NCT03746704
Study type Interventional
Source Regeneron Pharmaceuticals
Contact Clinical Trials Administrator
Phone 844-734-6643
Email [email protected]
Status Recruiting
Phase Phase 1
Start date September 4, 2019
Completion date November 13, 2023